Early identification of prodromes in neurodegenerative diseases is of great importance for understanding the course of and potential for interventions in progressive cognitive change. Prodromal Alzheimer's disease may manifest in multiple cognitive domains, including memory or executive deficits, making it difficult to distinguish from other prodromal pathophysiologies such as frontotemporal dementia. This project addresses this difficulty by combining structural and functional markers of network integrity with novel measures of white matter disruption using the recently developed NIH Human Connectome Project scanner. This state-of-the-art instrument was developed for high fidelity imaging of the integrity of white matter fiber tracts, but also allows conventional imaging. These technical advantages are leveraged by the project aims. The project focus is on subjects with subjective cognitive concerns or mild cognitive impairment exhibiting a phenotype of predominant executive dysfunction or of predominant memory deficits.
Aim 1 will test the hypothesis that these two cognitive phenotypes will be associated with structural and functional connectivity measures of the integrity in different networks.
Aim 2 will test the hypothesis that novel measures of white matter integrity using diffusion imaging on the Connectome Project scanner will improve sensitivity to early impairments in the these two cognitive phenotypes when paired with the structural and functional connectivity measures developed in Aim 1. Because of the novelty of the Connectome methods, we will assess the sensitivity of fiber tract identification and integrity compared to conventional methods across a 3-year follow-up interval in a subset of subjects. The project addresses a growing need for early identification and differential diagnosis of individuals who will go on to develop different neurodegenerative diseases so that they can be targeted for participation in clinical trials or lifestyle interventions. Successful completion of the aims will contribute novel neuroimaging markers of prodromal neurodegenerative diseases and will further scientific knowledge of the relationship between functional network integrity and the integrity of fiber tracts connecting key nodes within a network.
|Viswanathan, Anand; Greenberg, Steven M; Scheltens, Philip (2016) Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment. Stroke 47:577-80|
|Dhilla Albers, Alefiya; Asafu-Adjei, Josephine; Delaney, Mary K et al. (2016) Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. Ann Neurol 80:846-857|
|Day, Gregory S; Musiek, Erik S; Roe, Catherine M et al. (2016) Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol 73:1125-32|
|Ronquillo, Jay Geronimo; Baer, Merritt Rachel; Lester, William T (2016) Sex-specific patterns and differences in dementia and Alzheimer's disease using informatics approaches. J Women Aging 28:403-11|
|Herold, C; Hooli, B V; Mullin, K et al. (2016) Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3. Mol Psychiatry 21:1608-1612|
|Serrano-Pozo, Alberto; Betensky, Rebecca A; Frosch, Matthew P et al. (2016) Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. Am J Pathol 186:375-84|
|Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-20|
|Ringman, John M; Monsell, Sarah; Ng, Denise W et al. (2016) Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol 75:284-90|
|Grogg, Kira S; Toole, Terrence; Ouyang, Jinsong et al. (2016) National Electrical Manufacturers Association and Clinical Evaluation of a Novel Brain PET/CT Scanner. J Nucl Med 57:646-52|
|Rentz, Dorene M; Dekhtyar, Maria; Sherman, Julia et al. (2016) The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis 3:8-12|
Showing the most recent 10 out of 717 publications